Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.

Cancer science - 1 Oct 2024

Matsui Yohei, Yamada Tadaaki, Katayama Yuki, Hirai Soichi, Sawada Ryo, Tachibana Yusuke, Ishida Masaki, Kawachi Hayato, Nakamura Ryota, Nishioka Naoya, Morimoto Kenji, Iwasaku Masahiro, Horinaka Mano, Sakai Toshiyuki, Tokuda Shinsaku, Takayama Koichi

Abstract excerpt

Lazertinib, a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), demonstrates marked efficacy in EGFR-mutant lung cancer. However, resistance commonly develops, prompting consideration of therapeutic strategies to overcome initial drug resistance mechanisms. This study aimed to elucidate the adaptive resistance to lazertinib and advocate novel combination treatments that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Axl Receptor Tyrosine Kinase
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Drug Resistance, Neoplasm

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 39039802
DOI: 10.1111/cas.16292
PMCID: PMC11447890

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.PMID 39039802Read ↗

AXL up-regulates PD-L1 inducing gefitinib resistance in EGFR mutated NSCLCSemantic proximity Read ↗

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.Semantic proximity Read ↗

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.Semantic proximity Read ↗

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinomaSemantic proximity Read ↗

Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancerSemantic proximity Read ↗

Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors.Semantic proximity Read ↗

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.Semantic proximity Read ↗

High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.Semantic proximity Read ↗

The battle against ALK resistance: successes and setbacksSemantic proximity Read ↗

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.Semantic proximity Read ↗

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.Semantic proximity Read ↗

Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.